Leidi.com Lei Jianping July 26
Carmell Therapeutics Corporation (CTCX.US), a biotechnology research and development company, recently completed the merger with Alpha Healthcare AcquisitionCorp.III (ALPA.US), a special purpose acquisition company, and listed on NASDAQ in the United States under the stock code "CTCX".
Carmell Therapeutics is a Phase II regenerative medicine platform company developing allogeneic plasma biomaterials ("Carmell") for active soft tissue repair, cosmetic and orthopedic indications, headquartered in Pittsburgh, PA, USA.
Before the merger, Carmell Therapeutics was valued at $150 million, and the combined company received approximately $154 million in SPAC financing at the close of the transaction.
The overall value of the new company after the merger is $328 million.
Rajiv Shukla will serve as executive chairman of the combined company and Randy Hubbell will serve as chief executive officer.
The following is the PPT of the biotech company Carmell’s roadshow (refined by Raidi.com):
———————————————
Lei Di was founded by Lei Jianping, a media person. If you reprint, please indicate the source.
